{"id":53808,"date":"2026-01-12T22:29:22","date_gmt":"2026-01-12T14:29:22","guid":{"rendered":"https:\/\/flcube.com\/?p=53808"},"modified":"2026-01-12T22:29:23","modified_gmt":"2026-01-12T14:29:23","slug":"lynk-pharmaceuticals-reports-positive-phase-iii-data-for-zemprocitinib-in-rheumatoid-arthritis-best-in-class-jak1-inhibitor-shows-79-acr20-response","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53808","title":{"rendered":"Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response"},"content":{"rendered":"\n<p><strong>Lynk Pharmaceuticals Co., Ltd.<\/strong> announced positive topline results from a pivotal Phase\u202fIII trial of <strong>zemprocitinib (LNK01001)<\/strong>, a highly selective second\u2011generation JAK1 inhibitor, in patients with <strong>moderate\u2011to\u2011severe active rheumatoid arthritis (RA)<\/strong> who had an inadequate response to biologic disease\u2011modifying antirheumatic drugs (bDMARDs).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Design<\/strong><\/td><td>Randomized, double\u2011blind, placebo\u2011controlled Phase\u202fIII<\/td><\/tr><tr><td><strong>Registration<\/strong><\/td><td>CTR20232969, NCT06276998<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>bDMARD\u2011IR RA patients (n\u202f=\u202f430)<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>ACR20 response at week\u202f24<\/td><\/tr><tr><td><strong>Key Secondary Endpoints<\/strong><\/td><td>ACR50, DAS28(CRP)\u202f\u2264\u202f3.2 at week\u202f24<\/td><\/tr><tr><td><strong>Topline Readout<\/strong><\/td><td>Statistically significant efficacy (p\u202f&lt;\u202f0.0001) across all primary and key secondary endpoints<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Highly selective, second\u2011generation <strong>JAK1 inhibitor<\/strong> with best\u2011in\u2011class potential<\/li>\n\n\n\n<li><strong>Selectivity:<\/strong> >200\u2011fold selectivity for JAK1 vs. JAK2\/JAK3, designed to reduce off\u2011target toxicities (anemia, neutropenia) seen with first\u2011generation pan\u2011JAK inhibitors<\/li>\n\n\n\n<li><strong>Indications in Development:<\/strong> Rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, vitiligo<\/li>\n\n\n\n<li><strong>Commercial Partnership:<\/strong> In March\u202f2022, Lynk Pharma signed an exclusive agreement with <strong>Simcere Pharmaceutical Group<\/strong> to co\u2011promote zemprocitinib for RA and ankylosing spondylitis in Greater China<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-iii-trial\">Clinical Evidence \u2013 Phase\u202fIII Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Zemprocitinib (n\u202f=\u202f~215)<\/th><th>Placebo (n\u202f=\u202f~215)<\/th><th>Treatment Difference<\/th><th>p\u2011value<\/th><\/tr><\/thead><tbody><tr><td><strong>ACR20 at Week\u202f24<\/strong><\/td><td><strong>79.1\u202f%<\/strong><\/td><td>39.7\u202f%<\/td><td>+39.4\u202fppt<\/td><td>&lt;\u202f0.0001<\/td><\/tr><tr><td><strong>ACR50 at Week\u202f24<\/strong><\/td><td><strong>55.8\u202f%<\/strong><\/td><td>22.0\u202f%<\/td><td>+33.8\u202fppt<\/td><td>&lt;\u202f0.0001<\/td><\/tr><tr><td><strong>DAS28(CRP)\u202f\u2264\u202f3.2 at Week\u202f24<\/strong><\/td><td><strong>51.2\u202f%<\/strong><\/td><td>15.0\u202f%<\/td><td>+36.2\u202fppt<\/td><td>&lt;\u202f0.0001<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>No Grade\u202f\u2265\u202f3 anemia; nasopharyngitis (12\u202f%), ALT elevation (8\u202f%)<\/td><td>\u2013<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The trial met its primary endpoint with a <strong>robust ACR20 response<\/strong>, demonstrating superiority over placebo in a hard\u2011to\u2011treat bDMARD\u2011IR population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China RA Market:<\/strong> ~4.5\u202fmillion diagnosed RA patients, with <strong>~800,000<\/strong> bDMARD\u2011IR candidates representing the addressable market for zemprocitinib.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Incumbent JAK inhibitors:<\/strong> Pfizer\u2019s Xeljanz (first\u2011gen, pan\u2011JAK) and AbbVie\u2019s Rinvoq (JAK1) hold ~65\u202f% of China\u2019s oral RA market.<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Zemprocitinib\u2019s superior JAK1 selectivity may translate into a better safety profile, particularly lower rates of anemia and thromboembolic events.<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Lynk projects <strong>\u00a51.8\u202fbillion<\/strong> (\u2248\u202fUS$250\u202fmillion) peak annual sales in China by 2029, assuming 15\u202f% share of the bDMARD\u2011IR segment.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Lynk plans to submit a <strong>New Drug Application (NDA)<\/strong> to NMPA in <strong>Q1\u202f2026<\/strong>, with potential approval by Q4\u202f2026. Simcere\u2019s 500\u2011person rheumatology sales force is being trained for launch.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory submissions, commercial forecasts, and market penetration for zemprocitinib. Actual results may differ due to competitive dynamics, pricing negotiations, and evolving treatment guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a pivotal Phase\u202fIII trial of zemprocitinib&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,1351],"class_list":["post-53808","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-lynk-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a pivotal Phase\u202fIII trial of zemprocitinib (LNK01001), a highly selective second\u2011generation JAK1 inhibitor, in patients with moderate\u2011to\u2011severe active rheumatoid arthritis (RA) who had an inadequate response to biologic disease\u2011modifying antirheumatic drugs (bDMARDs).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53808\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response\" \/>\n<meta property=\"og:description\" content=\"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a pivotal Phase\u202fIII trial of zemprocitinib (LNK01001), a highly selective second\u2011generation JAK1 inhibitor, in patients with moderate\u2011to\u2011severe active rheumatoid arthritis (RA) who had an inadequate response to biologic disease\u2011modifying antirheumatic drugs (bDMARDs).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53808\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T14:29:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T14:29:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53808#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53808\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response\",\"datePublished\":\"2026-01-12T14:29:22+00:00\",\"dateModified\":\"2026-01-12T14:29:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53808\"},\"wordCount\":408,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Lynk Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53808#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53808\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53808\",\"name\":\"Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T14:29:22+00:00\",\"dateModified\":\"2026-01-12T14:29:23+00:00\",\"description\":\"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a pivotal Phase\u202fIII trial of zemprocitinib (LNK01001), a highly selective second\u2011generation JAK1 inhibitor, in patients with moderate\u2011to\u2011severe active rheumatoid arthritis (RA) who had an inadequate response to biologic disease\u2011modifying antirheumatic drugs (bDMARDs).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53808#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53808\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53808#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response - Insight, China&#039;s Pharmaceutical Industry","description":"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a pivotal Phase\u202fIII trial of zemprocitinib (LNK01001), a highly selective second\u2011generation JAK1 inhibitor, in patients with moderate\u2011to\u2011severe active rheumatoid arthritis (RA) who had an inadequate response to biologic disease\u2011modifying antirheumatic drugs (bDMARDs).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53808","og_locale":"en_US","og_type":"article","og_title":"Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response","og_description":"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a pivotal Phase\u202fIII trial of zemprocitinib (LNK01001), a highly selective second\u2011generation JAK1 inhibitor, in patients with moderate\u2011to\u2011severe active rheumatoid arthritis (RA) who had an inadequate response to biologic disease\u2011modifying antirheumatic drugs (bDMARDs).","og_url":"https:\/\/flcube.com\/?p=53808","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T14:29:22+00:00","article_modified_time":"2026-01-12T14:29:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53808#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53808"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response","datePublished":"2026-01-12T14:29:22+00:00","dateModified":"2026-01-12T14:29:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53808"},"wordCount":408,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Lynk Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53808#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53808","url":"https:\/\/flcube.com\/?p=53808","name":"Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T14:29:22+00:00","dateModified":"2026-01-12T14:29:23+00:00","description":"Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a pivotal Phase\u202fIII trial of zemprocitinib (LNK01001), a highly selective second\u2011generation JAK1 inhibitor, in patients with moderate\u2011to\u2011severe active rheumatoid arthritis (RA) who had an inadequate response to biologic disease\u2011modifying antirheumatic drugs (bDMARDs).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53808#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53808"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53808#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lynk Pharmaceuticals Reports Positive Phase\u202fIII Data for Zemprocitinib in Rheumatoid Arthritis \u2013 Best\u2011in\u2011Class JAK1 Inhibitor Shows 79\u202f% ACR20 Response"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53808"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53808\/revisions"}],"predecessor-version":[{"id":53809,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53808\/revisions\/53809"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}